替加环素治疗多重耐药鲍曼不动杆菌感染的疗效观察  

Efficacy of tigecycline in the treatment of the infections caused by multidrug-resistant Acinetobacter baumannii

作　　者：郭晶[1] 张民伟[1] 陈菁[1] 宁耀贵[1] 

机构地区：[1]厦门大学附属第一医院重症医学科,厦门361000

出　　处：《实用药物与临床》2014年第9期1131-1135,共5页Practical Pharmacy and Clinical Remedies

摘　　要：目的回顾性分析替加环素治疗多重耐药鲍曼不动杆菌(MDRAB)的微生物学清除率及临床治疗效果。方法我院重症医学科2011年9月至2013年5月,26例确诊为MDRAB感染的患者。使用替加环素治疗,替加环素首剂100 mg,随后每12 h 50 mg静脉滴注,疗程≥5 d,收集其临床及微生物学相关资料。结果26例鲍曼不动杆菌感染患者应用替加环素治疗后17例(17/26,65.4%)临床治疗有效,22例(22/26,84.6%)微生物清除。14 d死亡率15.4%。4例(15.4%)因临床和细菌学反应差而在2周内死亡。其中血流感染9例中微生物学清除8例,临床治疗有效5例;肺部感染16例中微生物清除13例,临床治疗有效11例;1例血流感染合并肺部感染微生物和临床反应均成功。结论替加环素治疗MDRAB感染具有良好疗效。Objective To evaluate the microbiology and clinical efficacy of tigecycline on infection caused by multidrug-resistant Acinetobacter baumannii（MDRAB）.Methods 26 patients in ICU of our hospital from September 2011 to May 2013 who were diagnosed as MDRAB infection used tigecycline treatment,the first dose of tigecycline was 100 mg,followed by 50 mg every 12 b,the treatment period≥5 d.Patients＇ clinical and microbiological data were collected.Results After treated with tigecycline,microbiology clearance was 84.6％,clinical success rate was 65.4％,14-day mortality was 15.4％.4 patients（15.4％）died within 2 weeks due to poor clinical and bacteriological response.In 9 patients of bloodstream infection,8 patients microbiology cleared,5 patients of clinical treatment was effective.In 16 patients of pneumonia,13 patients microbiology cleared,11 patients of clinical treatment was effective.1 patient of pneumonia and bloodstream infection was success.Conclusion Tigecycline is effective in the treatment of MDRAB infection.

关 键 词：替加环素 鲍曼不动杆菌 医院感染 

分 类 号：R446.5[医药卫生—诊断学]